Although this meant that a heterologous infection model would be employed to assess the efficacy of S. haematobium proteins, we reasoned that the homology of the candidates between the two species could be sufficiently high (Sh-TSP2—69.6% identity, MS3_09198—98.6% identity, and MS3_01370—79.5% identity) (Figure S1) as to afford a level of cross-species protection and provide informative data with regards to the vaccine efficacy of these candidates. This evidence concerns the gene THBS2 and infection.